ストックスクリーナーアプリを入手
3.36
0.45%
0.03
前日終値:
$3.33
開ける：
$3.34
24時間の取引高:
158.90K
Relative Volume:
0.37
時価総額：
$145.22M
収益：
-
当期純損益:
$-110.66M
株価収益率:
-1.0852
EPS:
-3.0963
ネットキャッシュフロー:
$-97.76M
1週間 パフォーマンス:
-6.30%
1か月 パフォーマンス:
+31.18%
6か月 パフォーマンス:
+11.50%
1年 パフォーマンス:
-52.08%
1日の値動き範囲:
$3.32
$3.44
1週間の範囲:
$3.25
$3.56
52週間の値動き範囲:
$1.78
$8.78
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
名前
Kyverna Therapeutics Inc
セクター
電話
(510) 626-8331
住所
5980 HORTON STREET, EMERYVILLE
KYTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
3.36 | 147.38M | 0 | -110.66M | -97.76M | -3.0963 |
|
VRTX
Vertex Pharmaceuticals Inc
|
376.59 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.84 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
428.55 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
669.10 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
294.77 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-27 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-10-10 | 開始されました | UBS | Buy |
| 2024-10-09 | 開始されました | Rodman & Renshaw | Buy |
| 2024-07-03 | 開始されました | H.C. Wainwright | Neutral |
| 2024-03-04 | 開始されました | JP Morgan | Overweight |
| 2024-03-04 | 開始されました | Leerink Partners | Outperform |
| 2024-03-04 | 開始されました | Morgan Stanley | Overweight |
| 2024-03-04 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Kyverna Therapeutics Inc (KYTX) 最新ニュース
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $15.60 Average Target Price from Analysts - MarketBeat
Kyverna Therapeutics (KYTX) Expected to Announce Earnings on Monday - MarketBeat
What are analysts’ price targets for Kyverna Therapeutics Inc. in the next 12 monthsInvest confidently with data-driven strategies - Jammu Links News
What is the risk reward ratio of investing in Kyverna Therapeutics Inc. stockInvest confidently with expert support - Jammu Links News
How does Kyverna Therapeutics Inc. generate profit in a changing economyUnlock real-time stock alerts for quick profits - Jammu Links News
What are the latest earnings results for Kyverna Therapeutics Inc.Expert guidance for superior capital growth - Jammu Links News
What analysts say about Kyverna Therapeutics Inc. stockCapital growth strategies that work - Jammu Links News
Is Kyverna Therapeutics Inc. a growth stock or a value stockAchieve superior capital gains with smart trades - Jammu Links News
What institutional investors are buying Kyverna Therapeutics Inc. stockGet expert advice on portfolio optimization - Jammu Links News
What are Kyverna Therapeutics Inc. company’s key revenue driversOutstanding growth strategies - Jammu Links News
Does Kyverna Therapeutics Inc. stock perform well during market downturnsBuild wealth faster with consistent growth stocks - Jammu Links News
What are the technical indicators suggesting about Kyverna Therapeutics Inc.Build a portfolio for long-term financial success - Jammu Links News
Is it the right time to buy Kyverna Therapeutics Inc. stockCapitalize on fast-growing investment opportunities - Jammu Links News
How volatile is Kyverna Therapeutics Inc. stock compared to the marketDynamic profit expansion - Jammu Links News
What catalysts could drive Kyverna Therapeutics Inc. stock higher in 2025High-profit capital plays - Jammu Links News
Should I hold or sell Kyverna Therapeutics Inc. stock in 2025Maximize gains with professional stock picks - jammulinksnews.com
How strong is Kyverna Therapeutics Inc. company’s balance sheetStock Strategy Recommendation From AI Tools - Jammu Links News
Is Kyverna Therapeutics Inc. stock overvalued or undervaluedPost Market Guidance For Smart Trading - jammulinksnews.com
Exit strategy if you’re trapped in Kyverna Therapeutics Inc.Short Term Setup With Predictive Chart Confirmed - metal.it
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionKYTX - ACCESS Newswire
Analysts Apply Wyckoff Model to Kyverna Therapeutics Inc. StockPattern Detection for Entry Confirmation Enabled - beatles.ru
Trendlines Suggest Kyverna Therapeutics Inc. May Bottom Out SoonWeekly Return Pick Forecast Reports Show Trend - metal.it
Rising Star: Covington's Alicia Zhang - Law360
Kyverna Appoints New CFO to Guide Next Growth Phase - Insider Monkey
Kyverna Therapeutics to Host Virtual KOL Event on Neuroimmunology CAR T Franchise - AInvest
Leading Neurologists Reveal Game-Changing CAR T Treatment for Rare Autoimmune Disorders - Stock Titan
Published on: 2025-07-29 14:03:16 - metal.it
What does KYTX's flat EPS in 2024 indicate for investors? - AInvest
11 Best New Penny Stocks to Buy Right Now - Insider Monkey
What institutions are buying Kyverna Therapeutics Inc. stock nowDaily Smart Money Movement Monitor Activated - metal.it
Why did Kyverna's operating expenses surge in Q4 2024? - AInvest
How many analysts rate Kyverna Therapeutics Inc. as a “Buy”Breakout Stocks Strategy With Low Risk - jammulinksnews.com
Why is Kyverna Therapeutics Inc. stock attracting strong analyst attentionBest Dividend Tips From AI Tools - Jammu Links News
Published on: 2025-07-28 19:09:23 - metal.it
What is the dividend policy of Kyverna Therapeutics Inc. stockAchieve breakthrough gains with smart trades - Jammu Links News
Will Kyverna Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsHigh Return Investment Tips - Newser
Published on: 2025-07-27 18:04:27 - Jammu Links News
How Kyverna Therapeutics Inc. stock performs during market volatilityFree Access to Investment Community - Newser
Why Kyverna Therapeutics Inc. stock attracts strong analyst attentionFree Stock Movement Tracking - Newser
Kyverna Therapeutics Inc (KYTX) 財務データ
収益
当期純利益
現金流量
EPS
0.53%
0.00%
大文字化:
|
ボリューム (24 時間):